2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Artificial Intelligence (AI), Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

5913 Neutrophil-induced RIPK1-dependent endothelial progenitor cell injury impairs vascular repair in steroid-refractory acute graft-versus-host disease

Yixiao Kang, Qingxiao Song, MD, PhD2, Rui Wang, MD3, Xiaodong Xie Jr, PhD4, Fengjuan Tian5, Xi Zhang, MD6
1 Xinqiao Hospital of Army Medical University,China, Chongqing, China
2 Xinqiao Hospital of Army Medical University,China, Chongqing, China
3 Xinqiao Hospital of Army Medical University,China, Chongqing, China
4 Xinqiao Hospital of Army Medical University,China, Chongqing, China
5 Xinqiao Hospital of Army Medical University,China, Chongqing, China
6 Xinqiao Hospital of Army Medical University,China, Chongqing, China

Background:

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a major cause of mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Vascular endothelial injury is increasingly recognized as a hallmark of SR-aGVHD and contributes to tissue inflammation and barrier dysfunction. Although endothelial damage has largely been attributed to alloreactive T-cell responses, particularly cytotoxic CD8? T cells, whether innate immune cells directly impair endothelial repair remains unknown. Neutrophils have emerged as important mediators of aGVHD pathogenesis and have also been implicated in steroid-refractory disease. Endothelial progenitor cells (EPCs) maintain vascular regeneration following tissue injury. We therefore investigated whether activated neutrophils promote SR-aGVHD by disrupting EPC-mediated vascular repair.  

 Methods:

Using a murine model of SR-aGVHD, we characterized bone marrow endothelial progenitor cells (EPCs) defined as CD45?CD34?CD133?VEGFR2? cells, and evaluated EPC abundance, survival, and angiogenic function together with endothelial integrity in GVHD target organs, including the liver and gastrointestinal tract. Donor-derived neutrophil activation, reactive oxygen species (ROS) production, neutrophil extracellular trap (NET) formation, and RIPK1-associated cell death signaling were analyzed. Mechanistic studies were performed using EPC–neutrophil coculture, pharmacologic inhibition of ROS, NETs, and RIPK1, together with EPC adoptive transfer.

 Results:

In murine SR-aGVHD, widespread endothelial injury was observed in the liver and gastrointestinal tract, characterized by disruption of endothelial junction proteins, increased vascular permeability, and endothelial apoptosis. Phenotypically defined bone marrow EPCs (CD45?CD34?CD133?VEGFR2? cells) initially exhibited a compensatory expansion but progressively developed impaired proliferation, angiogenic capacity, migration, and increased apoptosis, resulting in depletion of the endogenous EPC compartment. Activated donor-derived neutrophils accumulated in GVHD target organs and produced excessive ROS and NETs. Mechanistically, neutrophils directly induced RIPK1-dependent apoptosis of EPCs through ROS and NETs formation, implicating the neutrophil-EPC axis as contributing to failure of vascular repair in GVHD. Pharmacologic inhibition of ROS, NETs, or RIPK1 attenuated EPCs injury and restored vascular integrity. Therapeutically, adoptive transfer of EPC purified from bone marrow in allo-BMT recipients restored endothelial repair, reduced endothelial apoptosis and vascular leakage, suppressed neutrophil activation, and significantly ameliorated SR-aGVHD, without compromising graft-versus-leukemia (GVL) activity.

 Conclusions:

These findings identify neutrophil-mediated disruption of EPC-dependent vascular repair as a pathogenic mechanism underlying SR-aGVHD. Activated donor-derived neutrophils induce ROS/NET-dependent RIPK1 activation and EPC apoptosis, linking innate immune activation to defective vascular regeneration and persistent tissue injury. Restoring EPC-mediated vascular repair or targeting RIPK1-dependent EPCs injury represents a promising therapeutic strategy for SR-aGVHD while preserving GVL activity.

Qingxiao Song, MD, PhD: No relevant conflicts of interest to declare.